Chapter 022

Nonopioid Analgesics, Nonsteroidal Anti-inflammatory Drugs, and Antirheumatic and Antigout Drugs

Elliot V. Hersh, Paul J. Desjardins, Clarence L. Trummel, and Stephen A.

CITED REFERENCES

  1. Barnett A, Kreutner W: Pharmacology of non-sedating H1 antihistamines. Agents Actions 33(Suppl):181-196, 1991. PUBMED Abstract
  2. Best CH, Dale HH, Dudley JW, et al: The nature of the vaso-dilator constituents of certain tissue extracts. J Physiol (London) 62:397-417, 1927. PUBMED Abstract
  3. Black JW, Duncan WA, Durant CJ, et al: Definition and antagonism of histamine H2-receptors. Nature 236:385-390, 1972. PUBMED Abstract
  4. Black JW, Duncan WA, Emmett JC, et al: Metiamide-an orally active histamine H2-receptor antagonist. Agents Actions 3:133-137, 1973. PUBMED Abstract
  5. Bovet D, Staub A: Action protectrice des éthers phénoliques au cours de l’intoxication histaminique. Compt Rend Soc de Biol 124:547-549, 1937.
  6. Busse W: New directions and dimensions in the treatment of allergic rhinitis. J Allergy Clin Immunol 82:890-900, 1988. PUBMED Abstract
  7. Carter CA, Wajciechowski NJ, Hayes JM, et al: Terfenadine, a nonsedating antihistamine. Drug Intell Clin Pharm 19:812-817, 1985. PUBMED Abstract
  8. Code CF: Reflections on histamine, gastric secretion, and the H2 receptor. N Engl J Med 296:1459-1462, 1977. PUBMED Abstract
  9. Crawford JM: The gastrointestinal tract. In Cotran RS, Kumar V, Collins T, editors: Robbins’ pathologic basis of disease, ed 6, Philadelphia, 1999, Saunders.
  10. Dale HH, Laidlaw PP: Histamine shock. J Physiol (London) 52:355-390, 1919. PUBMED Abstract
  11. Deakin M, Williams JG: Histamine H2-receptor antagonists in peptic ulcer disease: efficacy in healing peptic ulcers. Drugs 44:709-719, 1992. PUBMED Abstract
  12. Famotidine (Pepcid). Med Lett Drugs Ther 29:17-18, 1987.
  13. Ganellin CR, Durant GJ, Emmett JC: Some chemical aspects of histamine H2-receptor antagonists. Fed Proc 35:1924-1930, 1976. PUBMED Abstract
  14. Goldsmith P, Dowd PM: The new H1 antihistamines: treatment of urticaria and other clinical problems. Dermatol Clin 11:87-95, 1993. PUBMED Abstract
  15. Hansten PD: Drug interactions of gastrointestinal drugs. In Lewis JH, editor: A pharmacologic approach to gastrointestinal disorders, Baltimore, 1994, Williams & Wilkins.
  16. Hill SJ: Distribution, properties and functional characteristics of three classes of histamine receptors. Pharmacol Rev 42:45-83, 1990. PUBMED Abstract
  17. Hofstra CL, Desai PJ, Thurmond RL, et al: Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther 305:1212-1221, 2003. PUBMED Abstract
  18. Hough LB: Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol 59:415-419, 2001. PUBMED Abstract
  19. Imamura M, Poli E, Omonivi AT, et al: Unmasking of activated histamine H3 receptors in myocardial ischemia: their role as regulators of exocytotic norepinephrine release. J Pharmacol Exp Ther 271:1259-1266, 1994. PUBMED Abstract
  20. Jacobs RS, Catania H: Cimetidine. Drug Intell Clin Pharm 11:723-726, 1977.
  21. Lagunoff D, Martin TW, Read G: Agents that release histamine from mast cells. Annu Rev Pharmacol Toxicol 23:331-351, 1983. PUBMED Abstract
  22. Levi R, Allan G, Zavecz JH: Cardiac histamine receptors. Fed Proc 35:1942-1947, 1976. PUBMED Abstract
  23. Lewis T, Grant RT: Vascular reactions of the skin to injury, II: the liberation of a histamine-like substance in injured skin; the underlying causes of factitious urticaria and of wheals produced by burning; and observations upon the nervous control of certain skin reactions. Heart 11:209-265, 1924.
  24. Ling P, Ngo K, Nguyen S, et al: Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule up-regulation. Br J Pharmacol 142:161-178, 2004. PUBMED Abstract
  25. Malamed SF: Sedation: a guide to patient management, ed 4, St Louis, 2003, Mosby.
  26. McGuigan JE: A consideration of the adverse effects of cimetidine. Gastroenterology 80:181-192, 1981. PUBMED Abstract
  27. McTavish D, Sorkin EM: Azelastine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 38:778-800, 1989. PUBMED Abstract
  28. Metcalfe DD, Costa JJ, Burd PR: Mast cells, and basophils. In Gallin JI, Goldstein IM, Snyderman R, editors: Inflammation: basic principles and clinical correlates, ed 2, New York, 1992, Raven Press.
  29. Meyer RA, Jakubowski W: Use of tripelennamine and diphenhydramine as local anesthetics. J Am Dent Assoc 69:112-117, 1964. PUBMED Abstract
  30. Mosby’s drug consult for health professions, St Louis, 2006, Elsevier.
  31. Nathan C: Points of control in inflammation. Nature 420:846-856, 2002.
  32. NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease: Helicobacter pylori in peptic ulcer disease. JAMA 272:65-69, 1994. PUBMED Abstract
  33. Parsons ME: The antagonism of histamine H2-receptors in vitro and in vivo with particular reference to the actions of cimetidine. In Burland WL, Simkins MA, editors: Cimetidine. Proceedings of the Second International Symposium on Histamine H2-Receptor Antagonists, Amsterdam, 1977, Excerpta Medica Foundation.
  34. Peets EA, Jackson M, Symchowicz S: Metabolism of chlorpheniramine maleate in man. J Pharmacol Exp Ther 180:464-474, 1972. PUBMED Abstract
  35. Powell JR, Brody MJ: Identification and blockade of vascular H2 receptors. Fed Proc 35:1935-1941, 1976. PUBMED Abstract
  36. Prell GD, Green JP: Histamine as a neuroregulator. Annu Rev Neurosci 9:209-254, 1986. PUBMED Abstract
  37. Ranitidine (Zantac). Med Lett Drugs Ther 24:111-113, 1982.
  38. Reiner PB, Kamondi A: Mechanisms of antihistamine-induced sedation in the human brain: H1 receptor activation reduces a background leakage potassium current. Neuroscience 59:579-588, 1994. PUBMED Abstract
  39. Riley JF, West GB: The occurrence of histamine in mast cells. In Rocha e Silva M, editor: Histamine and antihistaminics, part 1. Handbook of experimental pharmacology, vol 18, Berlin, 1966, Springer-Verlag.
  40. Sawyer D, Conner CS, Scalley R: Cimetidine: adverse reactions and acute toxicity. Am J Hosp Pharm 38:188-197, 1981. PUBMED Abstract
  41. Schayer RW: Catabolism of histamine in vivo. In Rocha e Silva M, editor: Histamine and antihistaminics, part 1. Handbook of experimental pharmacology, vol 18, Berlin, 1966, Springer-Verlag.
  42. Schwartz J-C, Arang JM: Histamine. In Davis KL, Charney D, Coyle JT, et al, editors: Neuropsychopharmacology: the fifth generation of progress, Philadelphia, 2002, Lippincott Williams & Wilkins.
  43. Schwartz J-C, Barbin G, Duchemin A-M, et al: Histamine receptors in the brain and their possible functions. In Ganellin CR, Parsons ME, editors: Pharmacology of histamine receptors, Bristol, 1982, Wright-PSG.
  44. Schwartz LB: Mast cells: function and contents. Curr Opin Immunol 6:91-97, 1994. PUBMED Abstract
  45. Simons FE: Advances in H1-antihistamines. N Engl J Med 351:2203-2217, 2004. PUBMED Abstract
  46. Simons FE, Simons KJ: Clinical pharmacology of H1-antihistamines. Clin Allergy Immunol 17:141-178, 2002. PUBMED Abstract
  47. Skidgel RA, Erdös EG: Histamine, bradykinin, and their antagonists. In Brunton LL, Lazo, JS, Parker KL, editors: Goodman & Gilman’s the pharmacological basis of therapeutics, ed 11, New York, 2006, McGraw-Hill.
  48. Sorkin EM, Heel RC: Terfenadine: a review of its pharmacologic properties and therapeutic efficacy. Drugs 29:34-56, 1985. PUBMED Abstract
  49. Spencer CM, Faulds D, Peters DH: Cetirizine: a reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs 46:1055-1080, 1993. PUBMED Abstract
  50. Thurmond RL, Deais PJ, Dunford PF, et al: A potent and selective histamine H4 receptor antagonist with antiinflammatory properties. J Pharmacol Exp Ther 309:404-413, 2004.
  51. Thurmond RL, Gelfand WW, Dunford PF: The role of histamine H1 and H4 receptors in allergic inflammation. Nat Rev Drug Discov 7:4-53, 2008. PUBMED Abstract
  52. Townley RG: Cetirizine: a new H1 antagonist with antieosinophilic activity in chronic urticaria. J Am Acad Dermatol 25:668-674, 1991. PUBMED Abstract
  53. Welborn JF, Kane JP: Conduction anesthesia using diphenhydramine hydrochloride. J Am Dent Assoc 69:706-709, 1964. PUBMED Abstract
  54. Willoughby DA: Mediation of increased vascular permeability in inflammation. In Zweifach BW, Grant L, McClusky RT, editors: The inflammatory process, vol 2, ed 2, New York, 1973, Academic Press.
  55. Woolsey RL, Chen Y, Freiman JP, et al: Mechanism of the cardiotoxic actions of terfenadine. JAMA 269:1532-1536, 1993. PUBMED Abstract
  56. Zweifach BW: Microcirculation. Annu Rev Physiol 35:117-150, 1973. PUBMED Abstract

GENERAL REFERENCES

  1. Chan FKL, Lau JYW: Treatment of peptic ulcer disease. In Feldman M, Friedman LS, Brandt LJ, editors: Sleisenger & Fordtran’s gastrointestinal and liver disease: pathophysiology, diagnosis, management, ed 8, Philadelphia, 2006, Saunders.
  2. Gallin JI, Snyderman R, editors: Inflammation: basic principles and clinical correlates, ed 3, Philadelphia, 1999, Lippincott Williams & Wilkins.
  3. Simons FER, editor: Histamine and H1-receptor antagonists in allergic disease, ed 2, New York, 2002, Marcel Dekker.